For a straightforward, uncomplicated UTI, Bactrim is generally the better first choice. Both antibiotics clear the infection at nearly identical rates, but Cipro carries more serious potential side effects and is reserved as a second-line option by major treatment guidelines. That said, your specific situation, including local resistance patterns and drug allergies, can flip that recommendation.
Cure Rates Are Nearly Identical
In a large randomized trial of 688 women with uncomplicated lower UTIs, a three-day course of either drug produced almost the same results. Ciprofloxacin (Cipro) cleared the bacteria in 94% of patients, while trimethoprim-sulfamethoxazole (Bactrim) cleared it in 93%. Clinical success, meaning symptoms resolved, was 93% for Cipro and 95% for Bactrim. These differences are too small to be meaningful.
The one area where Cipro showed a slight edge was recurrence. At the four-to-six-week follow-up, 11% of Cipro-treated patients had a recurrence compared to 16% in the Bactrim group. That gap is worth noting if you deal with frequent UTIs, though it alone isn’t enough to override other considerations.
Why Guidelines Rank Bactrim Higher
The Infectious Diseases Society of America and related guidelines list Bactrim as a first-line treatment for uncomplicated cystitis, alongside nitrofurantoin and fosfomycin. Cipro and other fluoroquinolones are classified as second-tier options, appropriate mainly when you’re allergic to the first-line drugs or when the bacteria are resistant to them.
The reasoning isn’t about effectiveness. It’s about preserving fluoroquinolones for situations where they’re truly needed, like complicated kidney infections or cases where other antibiotics have failed. Overusing Cipro for simple bladder infections accelerates resistance, making it less reliable when it matters most. There’s also a significant safety gap between the two drugs, which plays heavily into the ranking.
Cipro Has More Serious Side Effects
The FDA has issued strong safety warnings for fluoroquinolones like Cipro, noting they are associated with disabling and potentially permanent side effects involving tendons, muscles, joints, nerves, and the central nervous system. These aren’t just theoretical risks. Tendon ruptures (particularly the Achilles tendon), peripheral neuropathy causing tingling or numbness, and mental health effects including confusion and anxiety have all been documented. For a simple bladder infection that Bactrim treats equally well, that risk profile is hard to justify.
Bactrim isn’t without its own concerns. It’s a sulfonamide antibiotic, and sulfa allergies are the second most commonly reported drug allergy after penicillin, affecting 3% to 6% of people. The most frequent reaction is a skin rash, but rare severe reactions including Stevens-Johnson syndrome can occur. If you have a known sulfa allergy, Bactrim is off the table entirely, and that’s one of the main situations where Cipro becomes the appropriate choice.
Resistance Is a Problem for Both
A large U.S. study tracking E. coli resistance from 2010 to 2022 found that susceptibility to both fluoroquinolones and Bactrim ranged from about 70% to 85% throughout the study period. That means roughly 15% to 30% of UTI-causing bacteria may not respond to either drug, depending on your region.
This is why urine cultures matter, especially if you’ve had recent antibiotic use or recurrent infections. If your local resistance rate for Bactrim exceeds 20%, guidelines suggest choosing a different first-line agent rather than jumping straight to Cipro. Your doctor may already know the resistance patterns in your area. If you’ve taken Bactrim recently and it didn’t work, resistance testing can determine whether Cipro is a better fit for your specific bacteria.
Treatment Duration
For uncomplicated UTIs in women, both drugs are typically prescribed for three days. That short course is one of Bactrim’s advantages over nitrofurantoin, which requires five days. For men, UTIs are generally treated as complicated infections, and both Bactrim and Cipro courses extend to at least 7 to 14 days. European urology guidelines specifically recommend either drug for male cystitis, chosen based on susceptibility testing.
Cost Comparison
Without insurance, generic ciprofloxacin is actually cheaper. A supply of 100 tablets runs roughly $27 to $71, while 100 tablets of generic Bactrim costs around $149. For a three-day UTI course you’d only need six tablets of either, so the out-of-pocket difference is modest. Both are available as inexpensive generics, and most insurance plans cover them at the lowest copay tier.
Pregnancy Changes the Calculation
Neither drug is a great option during pregnancy, but for different reasons. Cipro is avoided entirely because fluoroquinolones are toxic to developing cartilage in the fetus. Bactrim is avoided during the first trimester (it can interfere with folic acid metabolism during early development) and the third trimester (it raises the risk of newborn jaundice). Pregnant women with UTIs are typically prescribed other antibiotics entirely, such as nitrofurantoin or certain penicillin-type drugs, depending on the trimester.
When Cipro Makes More Sense
Cipro becomes the right choice in a few specific scenarios. If you have a sulfa allergy, Bactrim is ruled out. If a urine culture shows your bacteria are resistant to Bactrim but sensitive to Cipro, the decision is straightforward. Cipro is also preferred for complicated UTIs that involve the kidneys (pyelonephritis) or that occur alongside structural urinary tract problems, because it penetrates tissue more effectively and is proven in those more serious infections.
For a routine bladder infection in an otherwise healthy person, though, Bactrim does the job with fewer risks. The two drugs kill bacteria through completely different mechanisms: Cipro disrupts the enzymes bacteria need to copy their DNA, while Bactrim blocks two steps in the pathway bacteria use to make folic acid (which they need to grow). Both are effective, but the safety and stewardship arguments consistently favor Bactrim as the starting point.